Hims & Hers Health (NYSE:HIMS) Downgraded to Hold Rating by TD Cowen

Hims & Hers Health (NYSE:HIMS) was downgraded by equities researchers at TD Cowen from a “buy” rating to a “hold” rating in a research note issued on Tuesday,Briefing.com Automated Import reports. They presently have a $30.00 price objective on the stock. TD Cowen’s target price points to a potential upside of 5.23% from the stock’s previous close.

A number of other research analysts have also commented on HIMS. Bank of America raised their price target on Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a report on Tuesday, March 18th. Truist Financial lowered their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating on the stock in a research note on Thursday, April 10th. Citigroup reduced their price objective on shares of Hims & Hers Health from $27.00 to $25.00 and set a “sell” rating for the company in a report on Friday. Morgan Stanley lowered shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their target price for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Finally, Leerink Partners increased their price target on Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research note on Tuesday, February 25th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $38.25.

Hims & Hers Health Price Performance

HIMS opened at $28.51 on Tuesday. The stock’s 50 day simple moving average is $33.44 and its 200 day simple moving average is $31.15. The stock has a market cap of $6.33 billion, a P/E ratio of 64.80 and a beta of 1.65. Hims & Hers Health has a 1-year low of $11.20 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Research analysts expect that Hims & Hers Health will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Irene Becklund sold 2,203 shares of the stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total transaction of $63,402.34. Following the completion of the sale, the insider now owns 8,007 shares in the company, valued at approximately $230,441.46. This trade represents a 21.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Melissa Baird sold 33,333 shares of the firm’s stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $25.78, for a total value of $859,324.74. Following the transaction, the chief operating officer now owns 805,083 shares of the company’s stock, valued at $20,755,039.74. This represents a 3.98 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 712,998 shares of company stock worth $27,992,450 over the last three months. Company insiders own 17.71% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently bought and sold shares of HIMS. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter valued at approximately $28,000. Raleigh Capital Management Inc. grew its stake in Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares during the period. Blume Capital Management Inc. grew its stake in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 600 shares during the period. Smartleaf Asset Management LLC grew its stake in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after acquiring an additional 1,413 shares during the period. Finally, Summit Securities Group LLC acquired a new stake in Hims & Hers Health during the 4th quarter worth $38,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.